These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8668340)

  • 1. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors.
    Wertheim I; Tangir J; Muto MG; Welch WR; Berkowitz RS; Chen WY; Mok SC
    Oncogene; 1996 May; 12(10):2147-53. PubMed ID: 8668340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas.
    Edelson MI; Scherer SW; Tsui LC; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Oncogene; 1997 Jun; 14(24):2979-84. PubMed ID: 9205105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors.
    Rodabaugh KJ; Biggs RB; Qureshi JA; Barrett AJ; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Oncogene; 1995 Oct; 11(7):1249-54. PubMed ID: 7478544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
    Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
    Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors.
    Rodabaugh KJ; Blanchard G; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Cancer Res; 1995 May; 55(10):2169-72. PubMed ID: 7743519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors.
    Edelson MI; Lau CC; Colitti CV; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Oncogene; 1998 Jan; 16(2):197-202. PubMed ID: 9464537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epithelial ovarian cancer allelotype.
    Cliby W; Ritland S; Hartmann L; Dodson M; Halling KC; Keeney G; Podratz KC; Jenkins RB
    Cancer Res; 1993 May; 53(10 Suppl):2393-8. PubMed ID: 8485726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
    Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
    Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer.
    Huang H; Reed CP; Mordi A; Lomberk G; Wang L; Shridhar V; Hartmann L; Jenkins R; Smith DI
    Genes Chromosomes Cancer; 1999 Jan; 24(1):48-55. PubMed ID: 9892108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
    Tangir J; Muto MG; Berkowitz RS; Welch WR; Bell DA; Mok SC
    Oncogene; 1996 Feb; 12(4):735-40. PubMed ID: 8632895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.
    Jacobs IJ; Smith SA; Wiseman RW; Futreal PA; Harrington T; Osborne RJ; Leech V; Molyneux A; Berchuck A; Ponder BA
    Cancer Res; 1993 Mar; 53(6):1218-21. PubMed ID: 8095178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.
    Dodson MK; Cliby WA; Xu HJ; DeLacey KA; Hu SX; Keeney GL; Li J; Podratz KC; Jenkins RB; Benedict WF
    Cancer Res; 1994 Feb; 54(3):610-3. PubMed ID: 8306318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of chromosome 3p deletions in human epithelial ovarian tumors.
    Lounis H; Mes-Masson AM; Dion F; Bradley WE; Seymour RJ; Provencher D; Tonin PN
    Oncogene; 1998 Nov; 17(18):2359-65. PubMed ID: 9811467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group.
    Eccles DM; Russell SE; Haites NE; Atkinson R; Bell DW; Gruber L; Hickey I; Kelly K; Kitchener H; Leonard R
    Oncogene; 1992 Oct; 7(10):2069-72. PubMed ID: 1408149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
    Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
    Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers.
    Wiper DW; Zanotti KM; Kennedy AW; Belinson JL; Casey G
    Gynecol Oncol; 1998 Oct; 71(1):77-82. PubMed ID: 9784323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic changes associated with ovarian cancer.
    Weitzel JN; Patel J; Smith DM; Goodman A; Safaii H; Ball HG
    Gynecol Oncol; 1994 Nov; 55(2):245-52. PubMed ID: 7959292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
    Gao X; Zacharek A; Salkowski A; Grignon DJ; Sakr W; Porter AT; Honn KV
    Cancer Res; 1995 Mar; 55(5):1002-5. PubMed ID: 7866981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
    Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
    Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
    Phelan CM; Borg A; Cuny M; Crichton DN; Baldersson T; Andersen TI; Caligo MA; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon YJ; Scherneck S; Barkardottir R; Borresen-Dale AL; Eyfjörd J; Theillet C; Thompson AM; Larsson C
    Cancer Res; 1998 Mar; 58(5):1004-12. PubMed ID: 9500463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.